Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer

Clinical Colorectal Cancer(2022)10.1016/j.clcc.2022.05.001Source: DataRank Database

Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer is a research paper published in Clinical Colorectal Cancer (2022). On theSindex it has a DataRank of 0. It has been cited 40 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access40 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 3.44)OA: greenTopics (40)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Stephanie Tapp ORCID,Allan T. Daly,Jonathan A. Busam ORCID,Anna N.A. Tosteson ORCID,Gabriel A. Brooks ORCID

Live enrichment

PubMed:35668003 PMC:PMC10496767 OpenAlex:https://openalex.org/W4280565697

National Cancer Institute

Grant: 5P30CA023108

Dartmouth SYNERGY Clinical and Translational Science Institute

Grant: UL1TR001086

NCI NIH HHS

Grant: P30 CA023108

National Center for Advancing Translational Sciences

Norris Cotton Cancer Center

National Institutes of Health

FWCI

3.44

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10496767/pdf/nihms-1929600.pdf

publisherhttps://api.elsevier.com/content/article/PII:S153300282200055X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S153300282200055X?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10496767

Fields of Study

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancerBiochemical and Molecular ResearchCapecitabineChemotherapy, AdjuvantColonic NeoplasmsCost-Benefit AnalysisDihydropyrimidine Dehydrogenase DeficiencyDihydrouracil Dehydrogenase (NADP)FluorouracilGenotypeHumans

MeSH Terms

CapecitabineColonic NeoplasmsCost-Benefit AnalysisFluorouracilGenotypeHumansChemotherapy, AdjuvantDihydrouracil Dehydrogenase (NADP)Dihydropyrimidine Dehydrogenase Deficiency

Keywords

DPYDMedicineDihydropyrimidine dehydrogenaseCapecitabineColorectal cancerGenotypingOncologyInternal medicineFluorouracilChemotherapyPharmacogeneticsCancerGenotypeThymidylate synthaseBiologyGeneticsGene5-fluorouracilDpd Deficiency

Sustainable Development Goals

SDG 0: Good health and well-being